BV-NSCLC- 002 (Cimavax) for non-small-cell lung cancer wild type EGF receptor positive patients

BV-NSCLC-002 is a new vaccine being develop to treat patients with advanced non-small cell lung cancer where the cells have a specific mutation (referred to as EGFR positive). The treatment is given as an injection at four sites after first-line chemotherapy then a reduced dose is given at two sites during the pre-progression phase.A study is currently determining how safe and efficacious BV-NSCLC-002 is in inoperable, late stage non-small cell lung cancer patients. If licensed it will offer an additional and more specific treatment option for patients with advanced EGFR positive non-small cell lung cancer and may improve survival.